Please login to the form below

Not currently logged in
Email:
Password:

GalNAc

This page shows the latest GalNAc news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

This approach will be combined with a liver-targeting delivery technology in development at Pfizer that involves binding RNA drugs to the amno acid N-acetylgalactosamine (GalNAc). ... The deal gives WAVE scope to use GalNAc in certain projects that lie

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    targets. The overt focus on liver disease has led to one new system for delivering siRNA to the liver, called GalNAc. ... GalNAc uses a specific sugar group attached to chemically-modified siRNA to target liver cells.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics